Asarfi Hospital Q2 profit rises 45% to ₹6.1 crore, margin 15.3%

Asarfi Hospital Limited, referred to as Asarfi Hospital, reported Q2 FY27 net profit of ₹6.1 crore, up 45%, while operating margin reached 15.3%. The result follows a Q1 FY27 in which consolidated revenue from operations stood at ₹47.5 crore and profit after tax was ₹4.3 crore, showing continued growth in the company’s reported financial performance.

What did Asarfi Hospital report for Q2 FY27?

Asarfi Hospital reported that Q2 FY27 net profit increased 45% to ₹6.1 crore and that operating margins reached 15.3%. The available company-related result summary does not specify Q2 revenue, EBITDA, or comparable quarterly operating-margin data, so these metrics cannot be assessed from the disclosed information.

The company had informed exchanges on November 6, 2026, that its board would meet on November 13 to consider and approve unaudited financial results for the quarter ended September 30, 2026. This placed the Q2 update within the company’s regular quarterly disclosure calendar under its listed-company reporting obligations.

The reported profit increase is significant because it follows a period of expansion in Asarfi Hospital’s operating scale. However, the supplied information does not provide a detailed Q2 cost breakdown, patient-volume data, occupancy figures, or segment-level performance. Investors therefore have limited visibility on the individual drivers of the reported margin level.

How did the Q1 FY27 financial performance compare?

Asarfi Hospital’s Q1 FY27 consolidated revenue from operations was ₹47.5 crore, compared with ₹35.7 crore in Q1 FY26, according to its investor presentation. The detailed presentation summary describes this as 32.8% year-on-year growth, while another summary of the presentation cites revenue growth of 33.2%.

Profit after tax in Q1 FY27 was reported at ₹4.3 crore, up 36.7% year-on-year. A separate Q1 summary specifies profit after tax of ₹4.27 crore, which is consistent with the rounded ₹4.3 crore figure. The company has not published an earnings-call transcript for Q1 FY27, and the disclosed figures are therefore presentation-based rather than management guidance from a call.

What are Asarfi Hospital’s FY27 financial targets?

Asarfi Hospital has reiterated a FY27 revenue target of ₹260 crore, an EBITDA margin of at least 22%, and a profit-after-tax margin range of 13% to 15%. Management described the revenue objective as implying growth of about 50% over FY26 consolidated revenue of ₹173.5 crore.

For FY26, the company reported consolidated EBITDA of ₹35.3 crore, up 42%, with an EBITDA margin of 20%. Against that base, the stated FY27 margin target indicates that management is seeking an improvement in profitability alongside revenue expansion. The Q2 reported operating margin of 15.3% should not be treated as directly comparable with the FY27 EBITDA-margin target because the source does not define both measures on the same basis.

Management has linked its growth plan to improving case mix, expanding geographically and applying cost measures. These are stated operational priorities, not reported outcomes for the September quarter. The available material also does not state whether any new capacity or geographic initiative contributed to Q2 performance.

What operating and financial issues remain relevant?

Asarfi Hospital has identified delayed approvals for bone-marrow transplant services as a constraint, with meaningful revenue from that activity expected to be pushed into FY28. This indicates that a potential specialised-care revenue stream is not expected to make a material contribution during FY27 based on management’s prior comments.

The company also cited pressure on cash realisation from government cashless schemes, with receivables aged around six to seven months. For hospital operators, delayed collections can affect working-capital requirements even when reported revenue and profit are growing. The supplied information does not quantify the total receivables balance or any effect on Q2 cash flow.

Near-term capital expenditure was described as less than ₹15 crore and expected to be funded largely through internal accruals. This relatively contained capex plan is relevant to investors because it suggests the company expects to support planned spending without specifying a major external funding requirement. No updated capex figure was provided in the Q2 material cited here.

How does the update matter for investors and hospital operations?

The Q2 profit figure and 15.3% operating margin give investors an updated indication of earnings performance as Asarfi Hospital works toward its FY27 targets. The Q1 revenue base of ₹47.5 crore and the FY26 revenue of ₹173.5 crore provide context for evaluating the ₹260 crore annual target, but the available disclosures do not provide enough Q2 revenue data to measure progress precisely.

For the hospital’s operations, management’s references to case mix, geographic expansion and cost measures point to the areas it considers important for growth and margins. At the same time, delayed transplant approvals and slower collections under government cashless schemes remain disclosed execution and cash-conversion considerations.

The company has used investor presentations and exchange filings to communicate financial updates. Its earlier Q2 and H1 FY26 disclosure had reported revenue growth of 45% year-on-year to ₹44.85 crore in Q2 and 50% year-on-year to ₹80.51 crore in H1. Those earlier figures provide historical context, but they do not substitute for a complete Q2 FY27 revenue disclosure.

Conclusion

Asarfi Hospital’s reported Q2 FY27 net profit of ₹6.1 crore, up 45%, and operating margin of 15.3% extend the financial progress indicated by its Q1 FY27 revenue and profit growth. The update supports the company’s focus on expanding scale and profitability, although the available information does not provide a complete quarterly revenue or cash-flow picture.

Investors will watch subsequent exchange disclosures for Q2 FY27 revenue, EBITDA, receivables and capex details, as well as progress toward the ₹260 crore FY27 revenue target and at least 22% EBITDA-margin objective. Updates on bone-marrow transplant approvals and the pace of collections from government cashless schemes will also remain relevant.